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THE PHAfuv,AGOW:nC TH1-:J\.TIILSNT OF AUHIGULAR F j ..BRILitATION

INTRODUCTION

Auricular fibrillation is the most common of all marked
irregu.larities of the heart beat in Qrganic heart disease.
For this reason, and because of the

gratifyin,~

results one

achieves from its treatment, I have chosen this subject as rry
topic.

'rhere will be no at tempt on the part of the student

to discuss the etiology, diagnosis" complications, or
incidence of this condition.

The mechanism of auricular

fibri llation ifJill be discussed as briefly as possible only to
more fully understand the rationale of its treatment.

1

There are four principal theories which have be;,m advanced
to explain the physiology of this condition.
They are:
1.

a rapidly beating ectopic pacemaker

2.

multiDle rapidly beating ectopic pacemakers

3.

continuous mult,iple reentries initiated by a single
or multi ole

4.

i~pulses

a self-perpetuat.ing mother ring caused by a sin'Sle
initial imp-ulse

At present the
1I'l:i.dely accepted.

la~ter

of these theories is the one most

In a review of the literature one finds

convincing arswnents both for and as;ainst each of the above
hypotheses.

HOV'T8ver as far as treatment of auricular fibrillaLion

is concerned, these theories are laYgely academi.c.

The

import.ant thing to realiz,e is that this condition is due to
the passage of excitation waVes through the non-refractory atrial
syncitiwn in an asynchronous fashion.

'rhus it rr.ay be eradicateo.

either by an over-all prolongation of the refractory phase
making the chamber unresponsive to the impulse, or by increasing
the speed at which these imDulses travel

80

that they would be

obliterated by arriving at regions before the absolute
refractory phase I-Jas over.

2

The treat.ment of atrial fibrillation has been and sdll
is a challanging problem.

There are three general types.

They are: chronic, acute, and thyrotoxic auricula.r
fibrillation.

The treatment of this condition (with the

exception of the latter tyne) consists mainly in the use of
three drugs--dL<;italis, quinidine, ar.d pronesGYl.

Atabrine,

fagarine, and chloroquine have been used, but vdth less
success.
Treatment of thyrotoxic atrial fibrillation consists of
treatment of the underlying or excit.ing condition.
Anti-coagulant drugs are
this lesion.

1.B

ed to treat a

c~)mplication

'1'his will be discussed below along withithe

drugs of choice.
Anti-thyroid Drugs
In most cases the above mentioned drugs aYe not so
useful in the treatment of th:rrotoxic atrial fibrillation.
One must treat the underlying or basic lesion, and in this
instance therapy consists of the ant.i-thyroid drugs.
For imr:cediate action, O. 5gm. of sodium iodine may be
given.

This should be followed by Lugol's solution in oral

dosage along with appropriate antt-tl1yroia t.nerapy.
Once the patient has been rendered euthroid by antit.b..yroid procedures, his cardiac problem is alm03t always

resolved"

If

sl~ch

is not the case, quiniaine is indicated,

3

of

and has been found oarticularly us eful in this instance.
Di~itali~

For many yea.rs digitalis w-as looked upon as influencin,s the
heart chiefly through slowini5 t:.he cardiac raGe, and was
hence thought specific for the treatment of atnal fibrillat.ion.
instead of being a specific anti-fibrillatory drug, digitalis
has in fact just the opposite effect.·

It actually increases

the rate of atrial fibrillaGion by a shortening of the
refractory period thereby allowing a greater rm.mber of
exci;:,a~L;n

waves to pass through the auriele.

Digitalis is administered not as a CIre Lr this condition, but merely as a cODljrul for it.

This drug is utilized

primi:i.rily to control the ventricular response in ;Jresenee of
atrial fibrillation.

It prevenc,s this conditlon from gOlng

on to ventricular tachycardia ard/or ventricular fibrillation,
b..:;th of \'lihlch have grave consequ8Eces for the patient.

rhe

dru.g accomplishes this c'.:ntrol phenomena by its action in
decreasing the conduct.ion .in the atrioventricular node and bundle
of His.

Thus a pharrnacolo:;;ic block is formed to protect the

ventricles.
Dif~italisls

also used with this condition because of its

beneficial effect upon carciiac

function~

This often alleviates

the anginal and/or cerebral ischemic symptoms frequently found
with atrial fibrillation.

4

This drug is being 'lsed le8':) often tociay for tile treatment
of atrial fibrilLation.

'l'his is becal.se thera()y is much less

conserva-sive than before.

A more agressive atsack is being advo-

cated with physicians being less selective in the patient t:.hey
try to conve:rt with the spacihc antifibrillatory dnigs.
IIDigita 1.ls is mainly indicated in the preser;ce of
congestive cardia.c failure, cardiac enlarseElent, in cases with
rapid ventricular rates, and in cases \-Jhere conversion to sinus

20.
rhythm vii t h quinidine has failed. !I
Classically, control is considered adequate when ['he

h(~art

rate is maintainec. around 85 beats per minute, without appreciable
increase in rate with moderate exercise.

.qS with other cardiac

conditions where digitalization is indicated, dosage ,nnst be
indiv::l.dualized.

The resultircg variations in cardiac reSiJonse

are related not only to the different characteristics of the
glycosides, but also to differing responses by individual
Datients.
Since there is ::nch a fine lir:e
di~italizati':)n

bet~feen

adequate

and toxicic.y, one must always be alert for

digitalis excess in trea::.ing this condition.

'I'he several ob-

jec Give clues ",;hich may harn the physician of the presence of
excess digitalis are:

"l.

further acceleration oi the ventri-

cular rate following di:?;italis admini3tration, 2.

obvious

independent activation of atria and ventricles (inordinately

5

slow, rapid, or precisely regular ventricular rates should be

"

sllspec:~8a),

3•

obvious group beatim; (bigeminy, trigeminy,

quadrageminy), 4.

determination of the rate of the accelerated
11.
nodal pacemaker to be b8t"veen 70-130 beats per min'J.te. II

'oluinidine is ;,he traditio:,al drug of choice for
treatment of atrial fibrillation.

ttll?-

"In apPl'oxima,tely t,nree

12..
fourths of the cases, quinidine is neces:3ary to effect revision"
to a normal sinus rhythm.
This drug El,cts as a myoca,rdial cJepreS3art.

27.

vveisman

~~

According to

depresses the sinoauricular node, increases the

refractory period, a.nd decreases ccmducT.ion time.

It causes

a prolongation of the P-H, QRS and S-T intat'vals.
Recently th.ere has been a great deal of controversy over
the selection of pat;i;.ents for conversion from atrial fibrilLation
to sinus rhythm.

Thou'Shts varied from those who felt that

conversion should be attempted in all instances to

::'h088

who

rejected conversion to normal sir:us rh;ytb...:m in all cases.
reasons for the latter opinion appear to be
that tliere is

V6

Y

Y

lit:~le supe.riori'~y

d~e

The

to t:,e belief

of simls rbythm over

di<sitalis controUed fibrillation, and a fear of the toyic
effects of quinidine.
Toxic side effects of quinidine inclu_oe "" a; group of '
symptoms knovm as cinchopism--tinnitus auriw;J, blurring of

.,,-

vision, vertigo, tremor, and light-headeoness as well as gastro-

6

7.

15.
Reports

intestinal disl.:.ress.'!

have also linked this aru.g

with the development of thrombocytopenic purpura.

~tl.ore

'fhe

serious complicat,i,)ns of quinidine are nroblably the cardiac

19.
These incl'lde S-A and AV blocks, and

arryt.hmias it produces.

ectopic rhythms of atrial, nodal, and ventricular origin.
Death during the course of quinide therapy is often due
to either asytole or respiratory oaralysis, neit,her of l,"hich
is too

surprisin~

in view of the fact that it ir.hibits acetyl
/

b.

choline which is thought to initiate the heart beat.

A myo-

cardial and respiratory depressing agent is given to an
already embarrasseC' myocardium and a physiologically impaired
respiratory center.
A healthy respect for quinidine is of COUrse understandable
in view of the fact that it is in reality cardiotoxic and
deaths have been reported in therapy.

In view of the beneficial

results attained with Draper quinidine therapy, it would appear
that the fears are la.rgely unfounded, especially if the proper
precautions are

observed~

4.
Brill

urges that the following precautions be utilized

when converting a patient with quinidine.

1.

Do not administer

this drug until full digitalization with a ventricular rate
of 80 or lower and

n~xium

compensation is achieved.

2.

Rule

out abnormal sensitivity to the drug with a 200 mg. test dose
on the day prior to the full dosage schedule.

7

3. Do not

fSive if the QRS

is~sreater

than 0.14 sec.

4.

Before each dose,

examine the patient and if hypotensive, or if there are
significant si:sns or symptoms of toxicity, st,op the drug.

5.

Frequent EKG's should be taken to dectect QR3 widening,

A-V dissociation, or cOYflplec:.e A-V block.
The advantages of sinus rhythm were well documented by

8-10.
Corday

who demonstrated using catheter techniques that atrial

fibrillation vIlth a rapid ventricular rate resulted in a reduction
in coro:nary artery flow, a les3ening of cerebral blood flow,
and a deminution of renal and mesenteric artery flow.
clinical

observa.t.ions:~they

In

have further sho1tm t,bat relief of

symptomatology (anrsirrl., dizziness) -which follov,s a normal sinus
rhythm can be correlated with improvement in blood flow to the
affected parts.

Patients have been reported who, before

conversion, had resoonded poorly to digitalization, became
free of symptoms after the establisDJ11ent of a normal sinus
rhythm.
It seems to be [,he consensus of opinion at this Gime that
conversion from atrial fibrillation to a normal sinus rhytJ:Iffi
should be attemptsd in all cases, except those in l'fhich a
contraindication to quinidine exists.

This drug is contra-

indicated when there is a coexistant intraventricular condu.ctiol1
defect or bundle

brar~ch

block, or ",hen atrial fibrillation is a

resutl of over-digitalization.

Quinidine is generall,y rejected

when sev",re congestive failure or v,hen the heart is severely
enlarged, and also when aerial fibrilla:,ion relieves
precordial pain;'.
Quir>idine is best adnLLnistered via the oral or B'l route.

IV quinidine ac1Jnini:3tration is !'raught vdth
that admir>istra,tion by this aV8Lue has

30

much hazard

lar~ely

been adbandoned.

in one series in which quinidine vJas given i ntravenou. sly , the

23.

1.
mort,ality rate

1NHS

10%.

Soko1mil

studied the effectiveness

of quinidine in the treatment of cardiac arrythmias and
correlat.ed serum levels with effective treat,ment.

The avera.ge

serum concentration which 75-80 per cent of patients "Ii"l/ith
atrial fibrillation converted inlaS 5.4 mg. per liter.

This level

vias achieved by aOlllinisLering the drug every t"m hours.

Thus,

it is lriidely accepted that the drug be given in divided doses

4.
at two hour intervals.

Brill recommends that quinidine su.lfate

U.S.P. be given hOO mg. five or six times
day.

dail~T

for the first

On each of the follovdng two days, providing the

arryLhrria continues and no toxic synwtoms appear, the dose is
increa.sed by an increment of 200 mg.

The dose ITIr3.Y be continued

for aofourth day v'Iithout change in dosage.
not continued beyond the fourth day.

The drug is usually

If conversion is not

achieved, a second and even a third attempt. may be atLempted at
intervals of several weeks.
of success with

rrhis meshod ha s met a high degree
\

Vc::)Y'Y

little toxicity if the preVIOusly described

prec1'Htions are adhered to.

9

Jllaintenance is largely a matter

of trial and error.

Unfort1.matel:r, no truly effective anecdote

16. & 19.
is not available for oVE:Or-dose of quinidine.
It is no longer felt that a Jrev:bous hisGory of embolism
contrainclicat'!s revision of a nOrlEal sinus rhythm through the

3.
use of ccuirddine.

The risk of an embolic episode in the natural

course of atrial fibrillation is considered greater than it is
during conversion to sinus rhythm using quinidine.

In patients

with a previous history of embolism, a cour-se of anti-coagulant
therar)Y is sl:,rongly recorrnnended as a prophylac I:,ie measure.
Prones.tyl
This drug is a comparatively new adcit.ion to the physicians'
armamentarium used against atrial fibrillation compared to

i" .

-"-,./

quinidine.

It produces in man a delayed conau.cGion rate and a

prolongation of the refractory period.
The posiLion of pronestyl in the treatrre nt of atrial
fibrillation appears m,Jre or less limited to the treaGment of the

18.
paroxysmal variety of this condition.

In one series, recent

atrial fibrillation (less than two weeks) responded to treatment
in 8-8% of the cases while the chronic variety (more than two
weeks) was treated suecessfull~v in only 21% of the cases.

Also,

in view of the limited experience we have wiLh procaine amide
as compared to quinidine, it waul·:} a'OiJear that the former drug
should be'J.sed \-/hen the latter cannot be tolerated.

This drug is

especially effacious in the treatment of acut.e atrial fibrillation

10

25.
since it may be aCJIrLnistered IV l,'fiTJh less danger than quinidine.
Contraindications and precautions to the use of pronest.yl
are essentially the same as those for quinidine.
Toxic side reactions have occurr<;3d involving the circulatory,
gastrointestinal, and central nervous system.

Ventricular

extrasystoles, ventricular tachycardia, and even ventricular
2.
Falls in BP during IV administration
fibrillation may occur.
have occurred in a number of patients, mostly those alreihdy
sufferini2; from a degree of hypotension with ventricular
Gastrointest,inal syr!1ptoms include anorexi~, nausea,
17.
' 14.
and vomiting. Chills and fever and a drug rash have been
tachycardia.

reported as well.
Kaydens recommends the following more or les3 general
dosa~e sc:~edule.

l"1it.h this drug as "lith other antifibrillatory

agents, individualization must be made.wing the EKG as the
main criterion of administration.

When pronestyl is administered

intravenously, it should not be:siven more than IJO mg. per
minute.

The d03e i3200 to

1,~)OO

mg. via this route.

the drug is given in capsules of J.25 gm., 1-2
1+-6 hours.

Orally,

capsules every

Intramuscular ly, it is rec ommended that it be given

one gm. four times a day.

Naintenance dosage should be continued

for aporoximately four weeks after revision to normal sinus
rhythm.

The latter dosage schedule is again emperical.

other

I~rugs

Due to the existence of the

11

rel~tively

safe, effective drugs

disc1J.S3eci (dL>;italis, quinidine, and prones Jyl), the dru.gs listeo
belNi have achieved little popularity.

They are mentioned

mainly for the sake of completeness.
Atabrine
Atabrine acts in much the same manner a,s quinidine, by
increasin..-g the refractory period of the myocaroium and by
decreasing its excitability.

This is not surprising as quin:ine,

the classic anti-malarial drug, v,as the first really successful
anti-fibrillatory drug used.
This drug is especially useful when quiro.idine .,as failed

24.
and with Datients who have coronary heart disease,
The dose is fromO.l to 0.2 gms. dissolved in 10-20 r.1l. of
normal saline, given by injection.
The us e of quinacrine is limited becaJ_se of its propensity
to cause ventricular fibrillatic,n.

Also, there may be a yellow

di;3coloration to the skin due to the deposition of an acridine
pigment.
Fagarine and Ghlorocluine
These drugs have also be:,n found ,~o have anwi-fibrillatory
21. & 22.
properties.
This property, like that of quinidine, and atabrine

was found incidental to the treatmerrt of malaria.

It is felt

that these drugs act by deer-sasing the excitability of the
myocarclilJIlJ; hmveVel', thlS action has noe bE<:m proven In man.

They are adrrlini:3tered inesl'venously ln order to be effective

12

21.
in the revision of sinus rhythm. hov,ever, a safe dosage
schedule has yet to be worked out.

'The incidence of fatal

ventricular tachycardia and fibrillation in these drugs has
")')
.. "-.
been too hi:sh for them to be of much use.
,:..

13

SUhl':..4.EY

This paper deals, as far as possible, solely 1rr.i.:th the
pharmacolo2;ic treatment of atrial fibrillation.

The basic

mechanism of this condition is pointed out only to edify the
reason for the successful action of the antifibrillB.tury drugs.
The drugs discussed were di:sitalis, quinidine, and. pronestyl.
Atabrine, fag;arine, chlor0quine, and the treaUilent of
thyrotoxic atrial fibrillation are discussed briefly.
Treatn:.ent of thyrotoxic atrial fibrillation consis ~~S of
treating the basic disease process, thyrotoxicosis.

For

im:rr;ediate action, 0.5 :9ll. of sodiu.'11 iodide is given IV.

This

is fo1101-,eo by appropriate anti-thyroid. treatment.
It was pointed. ')ut -+:'hB.t ciigitalis is not a specific
treatment for this condition, but merely a Itcontroll' for it.
It prevents atrial fibrillation from going on to the more
serious ventricular tachycardia and/or fibrillation.

The

dru s accomplishes this control mechanism by creating a
pharmacolo:.sic block in t.he A-V node and b-lndle of His.

It is

also utilized because of its beneficial effect on cardiac
out,put.

Classically, control is considered adequate yo[hen the

ventricular rac:.e is kept a.round 80 beats per minute with no
aporeciable increase in rate with exercise.

Dosase must be

individualized in order to achieve adeq'.1ate control and yet
avoid the o)itfali of digitalis int,oxication.

Several objective

C1..ues to alert the physic:ia n to this hazard are listed..

Quinidine, the specific c-riJ_Z in the treatment of atrial
fibrillation, . is discussed in some detail.
condition, nOG merely

II control" ,

it.

It can

!l

curs " the

Some controversy

6y,iST,S

today in the selection of patients for the. revision of normal
sinus rhythm.

The old argunmnts that quinidine is to be feared

and that sinus rhythm is little superior to digitalis controlled
atrial fibriEation have largely been disproven.

Experimental

and clinical experiences ha. ve shovm the clear cut superiority
of a normal sir-us rhythm.

Also, if the listed precautions are

observed, the fears of quinidine are largely unfounded.

It would

seem that unless one of the recognized contraindications exist,
conversion from atrial fibrillation to normal sinus rhyt,J:lrH
should be attemptec: in all instances.

A dosage schedule and the

rationale for the schedule are disGussed E,.long ",;-ith a fe\llJ
ftiords

conc~:rning

en,bolsim during revision of the physiologic

heart beat.
It "fas pointed out that prorlc33tyl has much the same mode
of aCGion as does quinidine.

It is oest

U3

ed when the patient

cannot take quinidine, and when the arrhythmia is acute in
nature.

Contraindications ard orecautibns for this drug are

much the s["me as those for quill.i.dine.

An added value is that

pronestyl can be given IV much safer than rng.y quinidine.
a fairly effective anecdote is available.

Also,

A rough dosage

schedule and its untO"l'iard effects are discusseG.
The other drugs useo_ in the treatment of this condition--

J!.5

atabrine, fa :sarine, a.nd chloroquine
to malarial therapy.

\~ere

discovered incidental

They have met little )opularity because

of their tendency to cause vent,ricular L.A.chycardia andl or
fiJrilla. tion.

1~

CONCLLT:310N

1.

'fhyrotoxic auricular fibrillation is best treated by
attacking the basic disease process 1r.ith anti-thyroid
therapy.

2.

Digitalis is indicated to ilcontroli' auricular
fibrilJ_ation and to prepare the patient for revision to
norrnal sinus rhyt.hm.

3.

Revision to normal sinus rhycrm should be attempted
in all incidences unles3 there is a contraindication to
the use of quinidine (and pr<::mestyl).

4.

PronesT,yl is indicated when quinidine cannot be tolerated
by the patient, and in the revision of acute fibrillation.

5.

Fagarine, chloI'o.-'l'J.ine, and atabrine have met ltJith liGtle
popularity in the treatment of auricular fibrillation
because of their tendency to cause ventricular tachycardia
and/or fibrillation.
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